Advertisement

Topics

BioMolecular Therapeutics, Inc. Company Profile

02:35 EST 24th November 2017 | BioPortfolio

An early-stage biopharmaceutical company, BMT is pioneering the development of novel RNAi therapeutics to prevent and treat age-related macular degeneration based on the company's proprietary technology, asymmetric shorter-duplex siRNA (asiRNA). This novel RNAi technology significantly reduces deleterious side effects triggered by conventional siRNA, especially, the stimulation of the innate immune system, which makes it feasible to use asiRNA for the treatment of age-related macular degeneration, a disease to which RNAi therapeutics could not be developed using conventional siRNAs. Other potential applications for BMT's technology include therapeutics targeting infectious disease, such as herpes simplex virus (HSV), and cancer. A privately held company based in Suwon, South Korea, BMT was established in 2010.


News Articles [558 Associated News Articles listed on BioPortfolio]

Global Biomolecular Motor Market Research Report Forecast 2017 to 2022 [Report Updated: 09102017] Prices from USD $2800

Delivery of the Report will take 23 working days once order is placed.The Global Biomolecular Motor Market Research Report Forecast 20172022 is a valuable source of insightful data for business strate...

Concurrent with BMS acquisition, IFM Therapeutics spins off IFM Therapeutics LLC

Innate immunity-focused IFM Therapeutics is spinning off its non-oncology assets into the new company IFM Therapeutics LLC.

Novel Platform Uses Nanoparticles to Detect Peanut Allergies

A team of chemical and biomolecular engineers at the University of Notre Dame designed nanoparticles that mimic natural allergens by displaying each allergic component one at a time on their surfaces

DNA becomes primary target in fight against glioblastoma

By exploiting a brain tumor's own biology, researchers at FIU's Biomolecular Sciences Institute (BSI) are hoping to destroy glioblastoma, a deadly brain cancer with no known cure.

Deals this week: Nabriva Therapeutics, LifeMine Therapeutics, Aldeyra Therapeutics

Nabriva Therapeutics plans to raise $80m through an underwritten public offering of shares of its common stock.

ProQR spins out Amylon Therapeutics for CNS therapeutics

ProQR Therapeutics has spun out Amylon Therapeutics, a privately-held company focused on the development of therapies for central nervous system (CNS) disorders, with seed funding from a group of inst...

New therapeutic targets for osteoarthritis pain

A new review by David A. Walsh and Joanne Stocks in the September 2017 issue of SLAS Discovery (formerly the Journal of Biomolecular Screening) explores evolving treatments and future therapies for os...

Centri-Sep, biotechnology, molecular separations, Panagel, electrophoresis, neuroscience

Leading,manufacturer,of,Centri-Sep,Plasmid-Prep,Panagel,Centri-Spin,Psi-Clone,used,in,DNA,sequencing,electrophoresis,biomolecular,purification

PubMed Articles [598 Associated PubMed Articles listed on BioPortfolio]

Catalytic Metallodrugs: Substrate-Selective Metal Catalysts as Therapeutics.

Metal complexes that catalyze inactivation and degradation of biomolecular targets can be developed into novel therapeutics (catalytic metallodrugs) against a variety of diseases. Despite recent advan...

Response to Aslankurt et al. re: "Safety Profile of Stromal Hydration of Clear Corneal Incisions with Cefuroxime in the Mouse Model".

Is the Eye an Extension of the Brain in Central Nervous System Disease?

Impairment of elastic properties of the aorta in bicuspid aortic valve: relationship between biomolecular and aortic strain patterns.

Bicuspid aortic valve (BAV) is associated with aortic wall alterations. We aimed to detect any correlation between aortic elasticity and genetic and biomolecular patterns of elastin.

Retraction of: Azithromycin 1.5% Ophthalmic Solution for Blepharitis Treatment: Comparison of 14- Versus 30-Day Treatment; DOI: 10.1089/jop.2015.0099.

Clinical Trials [129 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1190 Associated Companies listed on BioPortfolio]

Centre for Molecular and Biomolecular Informatics

Welcome at the CMBI, which is short for Centre for Molecular and Biomolecular Informatics. The centre performs research and education, and provides services in bioinformatics and cheminformatics.

Association of Biomolecular Resource Facilities

The Association of Biomolecular Resource Facilities is an international society dedicated to advancing core and research biotechnology laboratories through research, communication, and education.

BioMolecular Therapeutics, Inc.

An early-stage biopharmaceutical company, BMT is pioneering the development of novel RNAi therapeutics to prevent and treat age-related macular degeneration based on the company's proprietary technolo...

Affigen

Affigen (www.affigen.com) develops tumor-identifying therapeutics that target cell lineage-specific tumor proteins in certain incurable cancers. The Company's growing team ...

Aquasome

A platform nanoparticulate technology for biomolecular delivery in a broad range of industrial, personal use, and biomedical applications.

More Information about "BioMolecular Therapeutics, Inc." on BioPortfolio

We have published hundreds of BioMolecular Therapeutics, Inc. news stories on BioPortfolio along with dozens of BioMolecular Therapeutics, Inc. Clinical Trials and PubMed Articles about BioMolecular Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioMolecular Therapeutics, Inc. Companies in our database. You can also find out about relevant BioMolecular Therapeutics, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record